๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Spain
Clinical trial register · European Union · CTIS

Clinical Trials in Spain

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12467 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 22 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,467
Total on CTIS
full historical archive
744
Phase III
within the shown window
Top member states
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527
Narrow the registerReset
Phase
Phase I 557 Phase I/II 211 Phase II 727 Phase III 744 Phase IV 261
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 47 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527 Belgium 424 Czechia 329
All 28 states
1018 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
2025-523871-44-00Cutaneous Manifestations of Lupus Erythematosus With or Witโ€ฆ
Merck Healthcare KGaA
Immune System Diseases
Spain, Belgium, France, Germany, Slovakia, Romania, Bulgaria, Italy, Poland, Greece
29/06/2026
Phase III
AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer
2025-521712-19-00Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Greece, Portugal, Germany, Belgium, Spain
29/06/2026
Phase II
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer
2025-524686-24-00Small Cell Lung Cancer
Pfizer Inc.
Neoplasms
France, Italy, Spain
29/06/2026
Phase IV
ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
2026-525500-10-00Obstructive sleep apnea syndrome, Obesity
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
Nutritional and Metabolic Diseases
Spain
29/06/2026
Phase II
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)
2025-523599-21-00Non-small Cell Lung Cancer
AstraZeneca AB
Neoplasms
Spain, Germany
29/06/2026
Phase I/II
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
2025-524623-50-00Solid Tumors
Revolution Medicines Inc.
Neoplasms
France, Poland, Ireland, Spain, Greece, Germany, Italy, Sweden, Belgium
29/06/2026
Phase II
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
2025-523288-39-00Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Mediar Therapeutics Inc.
Immune System Diseases
Netherlands, Romania, Poland, France, Italy, Spain
29/06/2026
Phase III
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00Pancreatic Ductal Adenocarcinoma
Incyte Corp.
Neoplasms
Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria
26/06/2026
Phase II
โ€œIn vivoโ€ biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.
2026-525628-13-00IgE-mediated respiratory allergic disease due to the allergโ€ฆ
Probelte Pharma S.L.
Disorders of Environmental Origin
Spain
26/06/2026
Phase III
A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
2025-523726-40-00Multiple Sclerosis
F. Hoffmann-La Roche AG
Immune System Diseases
Spain, France, Poland, Italy
24/06/2026
Phase IV
The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial
2025-524761-25-00infertility
Santiago Dexeus Font Fundacio Privada
Female Urogenital Diseases and Pregnancy Complications
Spain
23/06/2026
Phase II
A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).
2025-523403-29-00Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Spain, France, Netherlands, Germany
23/06/2026
Phase IV
USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.
2026-525766-21-01Hypoxemic episodes in patients undergoing gastroscopy, coloโ€ฆ
Hospital Universitario Rio Hortega
Respiratory Tract Diseases
Spain
23/06/2026
Phase III
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
2025-521353-16-00Hereditary Angioedema
Adarx Pharmaceuticals Inc.
Immune System Diseases
Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia
22/06/2026
Phase III
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
2025-524322-18-00Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC
Nervous System Diseases
Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia
22/06/2026
Phase II
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).
2025-524488-18-00Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc.
Neoplasms
Germany, France, Poland, Italy, Spain
22/06/2026
Phase II
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
2025-522587-33-00Narcolepsy with Cataplexy (NT1)
Takeda Development Center Americas Inc.
Nervous System Diseases
Spain, Italy, France
22/06/2026
Phase III
Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events
2025-524625-41-00Coronary atherosclerosis
Daiichi Sankyo Europe GmbH
Cardiovascular Diseases
Italy, Spain, Germany
22/06/2026
Phase I
Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivoยฎ as adjuvant monotherapy in patients with melanoma
2025-525158-20-00Stage IIB/C, Stage III, or Stage IV Melanoma
Biocon Biologics UK PLC
Neoplasms
Spain, Romania
22/06/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)
2025-524337-11-00Systemic Sclerosis
Celgene Corp.
Immune System Diseases
Spain, Germany, France, Italy, Belgium
19/06/2026
Phase IV
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
2025-523374-17-03Type 2 diabetes
Fundacio Hospital Universitari Vall Dโ€™Hebron Institut De Recerca
Nutritional and Metabolic Diseases
Spain
19/06/2026
Phase I/II
Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product
2024-514190-21-00Ornithine Transcarbamylase Deficiency (OTC)
Iecure Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, France
18/06/2026
Phase I
A study to check whether adding RUTIยฎ to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the bodyโ€™s defenses, with participants randomly receiving RUTIยฎ or a look-alike treatment.
2026-525897-20-00High-risk non-muscle invasive bladder cancer (NMIBC)
Laboratorio Reig Jofre S.A.
Male Urogenital Diseases
Spain
18/06/2026
Phase III
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO
2025-524048-36-00Advanced HER2-negative and PD-L1 positive gastroesophageal โ€ฆ
Fondazione GONO G.I.
Neoplasms
Spain, Germany, Italy
18/06/2026
Phase II
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
2024-513496-40-00PARKINSONโ€™S DISEASE
Universitaetsklinikum Tuebingen AรถR
Nervous System Diseases
Spain, Germany, Italy, Sweden, France, Luxembourg
18/06/2026
Phase I
Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer
2025-524687-38-00Other Solid Tumors Associated with Nectin-4 Expression, Relโ€ฆ
Rondo Therapeutics Inc.
Neoplasms
Spain
17/06/2026
Phase III
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
2025-522373-10-00Progressive pulmonary fibrosis and Idiopathic pulmonary fibโ€ฆ
Bristol-Myers Squibb Services Unlimited Company
Respiratory Tract Diseases
Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany
17/06/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period
2025-522294-11-00Systemic sclerosis
Galderma S.A.
Skin and Connective Tissue Diseases
Poland, Italy, Bulgaria, France, Greece, Spain, Croatia
17/06/2026
Phase I
Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer
2025-524690-16-00Solid Tumors
Theras Inc.
Neoplasms
Spain, Italy, France
16/06/2026
Phase II
A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
2025-525124-10-00Duchenne Muscular Dystrophy
Entrada Therapeutics Inc.
Musculoskeletal Diseases
Belgium, Italy, Netherlands, Spain
16/06/2026
Phase III
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
2024-519787-40-00Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Eโ€ฆ
AstraZeneca AB
Neoplasms
France, Italy, Spain, Hungary, Poland, Belgium, Germany, Netherlands
16/06/2026
Phase I/II
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)
2025-520626-37-00Metastatic Prostate Cancer
AstraZeneca AB
Neoplasms
Belgium, Spain, Poland, Italy, Netherlands
16/06/2026
Phase III
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
2025-522643-18-00Stage I NSCLC
Merck Sharp & Dohme LLC
Neoplasms
Greece, Poland, Italy, Hungary, Germany, Netherlands, France, Spain
16/06/2026
Phase II
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
2025-524640-35-00Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc.
Digestive System Diseases
Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania
16/06/2026
Phase III
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica
2024-511296-15-00Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement
Musculoskeletal Diseases
France, Netherlands, Germany, Czechia, Belgium, Austria, Hungary, Greece, Spain
15/06/2026
Phase IV
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
2025-524487-37-00C3 Glomerulopathy (C3G), Primary Immune Complex Membranoproโ€ฆ
Swedish Orphan Biovitrum AB (publ)
Immune System Diseases
France, Italy, Spain, Germany, Belgium
15/06/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)
2025-522038-29-00Locally advanced, unresected (unresectable or medically inoโ€ฆ
Merck Sharp & Dohme LLC
Neoplasms
Italy, Netherlands, France, Germany, Spain, Poland, Greece
12/06/2026
Phase III
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
2025-522267-15-00โ€‹Relapsed/refractory B-cell Acute Lymphoblastic Leukemiaโ€‹
Merck Sharp & Dohme LLC
Neoplasms
Greece, Netherlands, Sweden, France, Italy, Spain, Denmark
12/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
2025-523674-16-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Greece, Germany, Belgium, Netherlands, Poland, Italy, France, Spain, Bulgaria, Austria
12/06/2026
Phase I/II
Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.
2025-522449-23-00Refractory Lupus Nephritis
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Immune System Diseases
Spain
11/06/2026
Phase III
Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) โ€“ Protocol OMCOS
2026-525540-15-00chronic suppurative otitis media (CSOM)
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
Otorhinolaryngologic Diseases
Spain
11/06/2026
Phase II
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
2025-524095-27-00HER2-negative, unresectable, recurrent, and/or metastatic gโ€ฆ
Gilead Sciences Inc.
Neoplasms
Spain, France
11/06/2026
Phase IV
Clinical trial to evaluate the correlation between variation in intestinal lactase activity measured with LacTEST 0.45g and alteration of intestinal barrier integrity and/or intestinal permeability in patients with celiac disease
2026-525518-70-00Patients with celiac disease
Venter Pharma S.L.
Digestive System Diseases
Spain
11/06/2026
Phase III
A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.
2025-522777-10-00Follicular Lymphoma
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Germany, Greece, Italy, Poland
09/06/2026
Phase I/II
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
2025-523432-39-01Advanced KRAS G12D-Mutant Solid Tumors
Verastem Inc.
Neoplasms
Italy, France, Germany, Belgium, Spain, Netherlands
09/06/2026
Phase III
Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis
2025-524454-34-00Bronchiectasis
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
Respiratory Tract Diseases
Spain
09/06/2026
Phase III
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)
2025-522176-86-01Moderate Calcific Aortic Valve Stenosis (CAVS)
Kardigan Inc.
Cardiovascular Diseases
Norway, Czechia, Portugal, Austria, Poland, France, Spain
08/06/2026
Phase I/II
A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer
2025-521032-11-00Small cell lung cancer extensive stage
Merck Sharp & Dohme LLC
Neoplasms
Germany, Poland, Greece, Italy, France, Spain
08/06/2026
Phase II
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period
2025-522301-37-00Nonsegmental vitiligo
Novartis Pharma AG
Skin and Connective Tissue Diseases
Germany, Spain, Netherlands, France, Italy
08/06/2026
Phase III
PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP โ€“ TRIAL)
2026-525355-93-00ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus
Bacterial Infections and Mycoses
Spain
08/06/2026
Phase II
A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).
2025-523984-39-00Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Gilead Sciences Inc.
Neoplasms
Spain, Italy, France
08/06/2026
Phase III
Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?
2026-525783-18-00Laparoscopic cholecystectomy
Fundacion Biomedica Galicia Sur
Digestive System Diseases
Spain
08/06/2026
Phase I/II
A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study)
2025-525144-18-00Advanced or metastatic histologically confirmed soft tissueโ€ฆ
Medica Scientia Innovation Research S.L.
Neoplasms
Spain
08/06/2026
Phase III
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigatorโ€™s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
2025-522818-23-00Small Cell Lung Cancer (SCLC)
Zai Lab (US) LLC
Neoplasms
Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France
08/06/2026
Phase II
Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.
2026-525701-12-00Parkinson's disease
Universidad Rey Juan Carlos
Therapeutics
Spain
08/06/2026
Phase II
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
2024-518587-12-00MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Cโ€ฆ
Pfizer Inc.
Respiratory Tract Diseases
Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary
08/06/2026
Phase I
A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation
2025-523648-11-00adenocarcinoma of the colon or rectum
Bayer Consumer Care AG
Neoplasms
Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium
08/06/2026
Phase I/II
KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments
2025-523537-26-00Locally advanced or metastatic KRAS G12C-mutated non-small โ€ฆ
Novartis Pharma AG
Neoplasms
Spain, Italy, France, Denmark, Belgium
08/06/2026
Phase II
Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.
2025-524363-20-01HIV-1 infection
Instituto De Salud Carlos III
Virus Diseases
Spain
08/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
2025-523675-39-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Belgium, Greece, Poland, France, Spain, Bulgaria, Italy, Germany, Austria, Netherlands
08/06/2026
Phase II
Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
2023-504439-42-03alcohol dependence
Hospital Universitario 12 De Octubre
Behavioral Disciplines and Activities
Spain
08/06/2026
Phase III
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
2025-524894-17-00Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited
Eye Diseases
Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia
05/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
2025-523912-35-00Narcolepsy Type 2
Alkermes Inc.
Nervous System Diseases
Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland
04/06/2026
Phase I/II
A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.
2025-523939-18-00Amyotrofic Lateral Sclerosis (ALS)
Nura Bio Inc.
Nervous System Diseases
Poland, Netherlands, Italy, Spain
03/06/2026
Phase III
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
2025-524575-22-00Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited
Eye Diseases
Spain, Poland, Estonia, Latvia, Germany
03/06/2026
Phase I/II
A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.
2025-523590-42-00Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma Inc.
Neoplasms
Spain, Ireland, Italy, France, Romania
02/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-523911-13-00Narcolepsy Type 1
Alkermes Inc.
Nervous System Diseases
Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland
02/06/2026
Phase III
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naรฏve and Biologic-naรฏve Systemic Lupus Erythematosus (SUNFLOWER)
2025-523670-17-00Systemic lupus erythematosus
AstraZeneca AB
Immune System Diseases
Poland, Germany, Italy, France, Spain
02/06/2026
Phase III
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
2025-522434-32-00Hemophilia A Without Inhibitors
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary
01/06/2026
Phase III
Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests
2025-523426-40-00Allergy to Lepidoglyphus destructor
Inmunotek S.L.
Immune System Diseases
Spain
01/06/2026
Phase III
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
2022-502365-26-00Asthma
Novartis Pharma AG
Respiratory Tract Diseases
Poland, France, Slovakia, Spain, Hungary, Germany, Romania
01/06/2026
Phase III
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
2025-522435-33-00Hemophilia A
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France
01/06/2026
Phase II
Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib
2025-521126-15-00Chronic Myeloid Leukemia
Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
Neoplasms
Spain
01/06/2026
Phase III
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naั—ve Mantle Cell Lymphoma
2025-524241-27-00Treatment-naั—ve mantle cell lymphoma (MCL)
Innocare Pharma Inc.
Neoplasms
Poland, France, Czechia, Spain, Romania
01/06/2026
Phase I/II
An open-label, single-arm, phase 1/2 first-in-human study to assess the safety and efficacy of autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene (SGX-001) in paediatric and adult patients with chronic granulomatous disease caused by p47phox deficiency
2025-524423-50-00Chronic granulomatous disease (CGD) caused by p47phox deficโ€ฆ
Somagenetix AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Germany, Spain
29/05/2026
Phase II
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
Centre Hospitalier De Versailles
Hemic and Lymphatic Diseases
Germany, France, Czechia, Netherlands, Spain
29/05/2026
Phase I/II
C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.
2025-523523-21-00Locally Advanced or Metastatic Urothelial Cancer
Pfizer Inc.
Neoplasms
Netherlands, Spain
29/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
2025-523555-66-00Myelofibrosis
Novartis Pharma AG
Neoplasms
Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France
29/05/2026
Phase II
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VXโ€‘828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
2025-523400-72-00Cystic fibrosis
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase II
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
2025-523539-20-00Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences Inc.
Neoplasms
Bulgaria, France, Spain
28/05/2026
Phase I/II
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MKโ€‘1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma
2025-523005-15-00Non-Hodgkin Lymphoma
Merck Sharp & Dohme LLC
Neoplasms
Poland, Italy, France, Germany, Spain
28/05/2026
Phase I/II
A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC
2025-523276-23-00Extensive stage small cell lung cancer
Novartis Pharma AG
Neoplasms
Spain, France
27/05/2026
Phase II
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials
2025-523579-47-00moderate to severe rheumatoid arthritis (RA)
F. Hoffmann-La Roche AG
Immune System Diseases
Italy, Spain, Germany, France, Denmark, Poland, Belgium
27/05/2026
Phase III
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohnโ€™s Disease
2025-521590-13-00Moderately to Severely Active Crohnโ€™s Disease
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase III
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
2025-522949-22-00Duchenne muscular dystrophy
Solid Biosciences Inc.
Musculoskeletal Diseases
Spain, Netherlands, France, Italy, Belgium, Germany
26/05/2026
Phase I/II
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
2025-522339-32-00Neoplasm malignant
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia
26/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
2025-524040-35-00Severe uncontrolled asthma
Generate Biomedicines Inc.
Respiratory Tract Diseases
Italy, Slovakia, Spain, Ireland, Belgium, France, Estonia
26/05/2026
Phase III
D. pteronyssinus and D. farinae allergen extracts. Study of the sensitivity and specificity of the prick test diagnostic preparation
2025-522469-31-00Allergy to Dermatophagoides pteronyssinus, Allergy to Dermaโ€ฆ
Inmunotek S.L.
Immune System Diseases
Spain
25/05/2026
Phase II
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
2025-524181-26-00relapsed/refractory multiple myeloma
C4 Therapeutics Inc.
Hemic and Lymphatic Diseases
Italy, France, Spain, Poland
25/05/2026
Phase I
A study to test single and multiple doses of MER511 given to adults with Gravesโ€™ disease
2025-523823-23-00Gravesโ€™ disease
Merida Biosciences Inc.
Immune System Diseases
Spain
22/05/2026
Phase III
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy
2025-523576-23-00Unresectable Stage III non-small cell lung cancer without pโ€ฆ
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland
22/05/2026
Phase I/II
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
2025-524620-22-00Neoplasms benign malignant and unspecified (incl. cysts andโ€ฆ
Orion Corporation
Neoplasms
Finland, Denmark, Spain, France
22/05/2026
Phase II
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
2025-525013-23-00Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
Eikon Therapeutics Inc.
Neoplasms
Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland
21/05/2026
Phase II
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
2025-524367-20-00Adult patients with primary mitochondrial disease
Pharming Technologies B.V.
Metabolism
Belgium, Germany, Czechia, Spain, Denmark, Italy, France
21/05/2026
Phase I
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors
2025-524165-25-00Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
Spain, Denmark, Finland, France
21/05/2026
Phase II
An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up
2025-523280-38-00Thyroid Eye Disease
Amgen Inc.
Eye Diseases
Spain, Poland, France, Italy, Greece
20/05/2026
Phase III
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib
2025-524078-40-00Chronic Spontaneous Urticaria
Novartis Pharma AG
Skin and Connective Tissue Diseases
Germany, Spain, France, Poland, Bulgaria, Czechia
20/05/2026
Phase III
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
2025-523259-72-00Hidradenitis Suppurativa (HS)
Novartis Pharma AG
Immune System Diseases
Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy
20/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00Duchenne muscular dystrophy
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, Germany, France, Spain, Belgium, Poland, Netherlands
20/05/2026
Phase II
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
2025-524005-32-00Rheumatoid arthritis
Elevara Medicines Limited
Immune System Diseases
Czechia, Bulgaria, Hungary, Netherlands, Poland, Spain
19/05/2026
Rows per page Showing 201–300 of 1018
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-europe/country/spain?page=3

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.